Asfotase alfa, sold under the brand name Strensiq, is a medication used in the treatment of people with perinatal/infantile- and juvenile-onset hypophosphatasia.[5][6][7][8][9][10][11]
The most common side effects include injection site reactions, hypersensitivity reactions (such as difficulty breathing, nausea, dizziness and fever), lipodystrophy (a loss of fat tissue resulting in an indentation in the skin or a thickening of fat tissue resulting in a lump under the skin) at the injection site, and ectopic calcifications of the eyes and kidney.[7][6]
The enzyme tissue non-specific alkaline phosphatase (ALP) plays a key role in creating and maintaining healthy bones, and managing calcium and phosphate in the body. People with hypophosphatasia cannot make enough working ALP, which leads to weak bones. Asfotase alfa is a version of the human ALP enzyme and serves as a replacement, thereby increasing levels of working ALP.[6]
^"Asfotase alfa (Strensiq) Use During Pregnancy". Drugs.com. 15 July 2019. Retrieved 10 May 2020.
^"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^"Strensiq - Summary of Product Characteristics (SmPC)". (emc). 21 January 2020. Retrieved 10 May 2020.
^"Strensiq- asfotase alfa solution". DailyMed. 7 February 2018. Retrieved 10 May 2020.
^ abcCite error: The named reference Strensiq EPAR was invoked but never defined (see the help page).
^ ab"FDA approves new treatment for rare metabolic disorder". U.S. Food and Drug Administration (FDA) (Press release). 24 October 2015. Archived from the original on 24 October 2015. Retrieved 11 May 2020. This article incorporates text from this source, which is in the public domain.
^U.S. Patent 7,763,712.
^Scott LJ (February 2016). "Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia". Drugs. 76 (2): 255–62. doi:10.1007/s40265-015-0535-2. PMID 26744272. S2CID 23910180.
^Hofmann C, Seefried L, Jakob F (May 2016). "Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia". Drugs of Today. 52 (5). Barcelona, Spain: 271–85. doi:10.1358/dot.2016.52.5.2482878. PMID 27376160.
^Bowden SA, Foster BL (2018). "Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy". Drug Design, Development and Therapy. 12: 3147–3161. doi:10.2147/DDDT.S154922. PMC 6161731. PMID 30288020.
Asfotasealfa, sold under the brand name Strensiq, is a medication used in the treatment of people with perinatal/infantile- and juvenile-onset hypophosphatasia...
paroxysmal nocturnal hemoglobinuria (PNH); asfotasealfa (Strensiq), used to treat hypophosphatasia; sebelipase alfa (Kanuma), used to treat lysosomal acid...
Andexanet alfa, sold under the brand name Andexxa among others, is an antidote for the medications rivaroxaban and apixaban, when reversal of anticoagulation...
analysis is possible and available in 3 laboratories. As of October 2015, asfotasealfa (Strensiq) has been approved by the FDA for the treatment of hypophosphatasia...
Global Information
This article incorporates text from this source, which is in the public domain.
